Cariprazine

Cariprazine
Clinical data
Pronunciation/kəˈrɪprəˌzn/
Trade namesVraylar, Reagila, Symvenu
Other namesRGH-188
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration
By mouth
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityHigh
Protein binding91–97%
MetabolismLiver via CYP3A4 and to a lesser extent CYP2D6
Metabolitesdesmethylcariprazine, didesmethylcariprazine
Elimination half-life2–4 days for parent drug, and 1–3 weeks for active metabolites
ExcretionUrine (21%), bile
Identifiers
  • N'-[trans-4-[2-[4-(2,3-Dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H32Cl2N4O
Molar mass427.41 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1
  • InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17- checkY
  • Key:KPWSJANDNDDRMB-QAQDUYKDSA-N checkY

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter,[8] which is used in the treatment of schizophrenia, bipolar mania,[9] bipolar depression,[10] and major depressive disorder.[6] It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor.[11] It is taken by mouth.[6]

Cariprazine was approved for medical use in the United States in September 2015.[12] It was approved as a generic medication in 2022,[13] but is covered by patents until 2029.[14]

Medical uses

Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder. In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).[15][6][16]

Cariprazine consistently improved depressive symptoms across a spectrum of patients with bipolar I depression.[17][18] In Australia, the United Kingdom, and the European Union it is approved only for treating schizophrenia.[5][7][19]

Side effects

Side effects may first appear several weeks after starting cariprazine.[6] The most prevalent side effects for cariprazine include akathisia and insomnia. Cariprazine does not appear to impact prolactin levels, and unlike many other antipsychotics, does not increase the QT interval on the electrocardiogram (ECG). In short term clinical trials extrapyramidal effects, sedation, akathisia, nausea, dizziness, vomiting, anxiety, and constipation were observed. One review characterized the frequency of these events as "not greatly different from that seen in patient treated with placebo"[20] but a second called the incidence of movement-related disorders "rather high".[21][22]

Regarding these side effects, the label of cariprazine states, "The possibility of lenticular changes or cataracts cannot be excluded at this time."[6]

Because cariprazine and its active metabolites have long half-lives, many healthcare professionals monitor for adverse effects up to several weeks after starting cariprazine. A longer monitoring period is also indicated for dosage changes, whether they represent an increase or a decrease, because elimination may take several weeks.[23]

Pharmacology

Pharmacodynamics

Cariprazine[24][15][25][26]
Site Ki (nM) IA (%) Action
5-HT1A 2.6 ~40% Partial agonist
5-HT2A 18.8 Antagonist
5-HT2B 0.58 Antagonist
5-HT2C 134 Inverse agonist
5-HT7 111 Antagonist
α1A 155 Antagonist
D2L 0.49 ~30% Partial agonist
D2S 0.69 ~30% Partial agonist
D3 0.085 ~70% Partial agonist
H1 23.2 Antagonist
mAChTooltip Muscarinic acetylcholine receptor >1,000 Antagonist
The smaller the Ki value, the more strongly the drug binds to the site. IA=intrinsic activity.

Unlike many antipsychotics that are D2 and 5-HT2A receptor antagonists, cariprazine is a D2 and D3 partial agonist. It also has a higher affinity for D3 receptors. The D2 and D3 receptors are important targets for the treatment of schizophrenia, because the overstimulation of dopamine receptors has been implicated as a possible cause of schizophrenia.[27] Cariprazine acts to inhibit overstimulated dopamine receptors (acting as an antagonist) and stimulate the same receptors when the endogenous dopamine levels are low. Cariprazine's high selectivity towards D3 receptors could prove to reduce side effects associated with the other antipsychotic drugs, because D3 receptors are mainly located in the ventral striatum and would not incur the same motor side effects (extrapyramidal symptoms) as drugs that act on dorsal striatum dopamine receptors.[28] Cariprazine also acts on 5-HT1A receptors, though the affinity is considerably lower than the affinity to dopamine receptors (seen in monkey and rat brain studies).[28][29] In the same studies, cariprazine has been noted to produce pro-cognitive effects, the mechanisms of which are currently under investigation. An example of pro-cognitive effects occurred in pre-clinical trials with rats: rats with cariprazine performed better in a scopolamine-induced learning impairment paradigm in a water labyrinth test. This may be due to the selective antagonist nature of D3 receptors, though further studies need to be conducted.[28] This result could be very useful for schizophrenia, as one of the symptoms includes cognitive deficits.

Cariprazine has partial agonist as well as antagonist properties depending on the endogenous dopamine levels. When endogenous dopamine levels are high (as is hypothesized in schizophrenic patients), cariprazine acts as an antagonist by blocking dopamine receptors. When endogenous dopamine levels are low, cariprazine acts more as an agonist, increasing dopamine receptor activity.[20] In monkey studies, the administration of increasing doses of cariprazine resulted in a dose-dependent and saturable reduction of specific binding. At the highest dose (300 μg/kg), the D2/D3 receptors were 94% occupied, while at the lowest dose (1 μg/kg), receptors were 5% occupied.[29] Dopamine D2 and D3 receptor occupancy in humans has been summarized as, "In healthy volunteers, single-dose cariprazine of 0.5 mg occupied up to 12% of striatal D2/D3 receptors, while striatal D2/D3 occupancy after multiple dosing up to cariprazine 1.0 mg/d ranged from 63 to 79% [39]. In an open-label, fixed-dose, 2-week trial in eight males with schizophrenia, PET scans of dorsal striatal regions (caudate nucleus and putamen) and ventral striatum (nucleus accumbens) showed maximum occupancy (‡ 90%) at a 3-mg target dose of cariprazine following 14 d of treatment [40,41]. After 14 d of cariprazine 1.5 mg/d, receptor occupancy was 69% in the caudate nucleus, 69% in the nucleus accumbens, and 75% in the putamen".[20]

Mechanism of cariprazine action as antagonist or agonist.

Cariprazine, as well as other third generation antipsychotics, possesses a lower chance of exacerbating extrapyramidal symptoms. However the ability to induce akathasia remains relatively high. This may be mediated through a lack of anticholinergic effects (as agents of this class are sometimes used to treat akathisia), as well as a lack of a balanced dopaminergic(D2)/serotonergic(5-HT2A) ratio (compared to the second generation antipsychotics serving a more nuanced profile in this regard)[clarify].[30][31][32] Moreover, partial agonists, through their limited response triggering, ironically often have the tendency to occupy near all targeted receptors at relatively low dosages of the drug. An extreme example is aripiprazole with an average occupancy of 70% (D2) at a 2 mg dose, well below its usual antipsychotic dosage (the often cited threshold of occupancy for an antipsychotic effect is 70%). This could be another reason for akathasia from partial agonists.[33][34]

Pharmacokinetics

Cariprazine has high oral bioavailability and can cross the blood brain barrier easily in humans because it is lipophilic.[35] In rats, the oral bioavailability was 52% (with a dose of 1 mg/kg).[22]

Cariprazine is metabolized primarily by the cytochrome P450 3A4 isoenzyme (CYP3A4), with some minor metabolism by CYP2D6. Cariprazine does not induce the production of CYP3A4 or CYP1A2 in the liver, and weakly, competitively inhibits CYP2D6 and CYP3A4.[15]

Research

Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar disorder I depression from a Phase II trial in 2015.[36][35]

Cariprazine is also potentially useful as an add-on therapy in major depressive disorder.[37] It is being developed jointly by AbbVie and Gedeon Richter Plc, with AbbVie responsible for commercialization in the US, Canada, Japan, Taiwan and certain Latin American countries (including Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Peru and Venezuela). In February 2022, AbbVie requested approval by the US Food and Drug Administration (FDA) for adjunctive treatment for major depressive disorder.[38] Approval was granted by the FDA in December 2022 for cariprazine to be used as an adjunctive treatment for major depressive disorder.[39]

References

  1. ^ a b "AusPAR: Cariprazine hydrochloride". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 4 January 2023. Retrieved 18 April 2023.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "Vraylar Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.
  4. ^ "Summary Basis of Decision - Vraylar". Health Canada. 26 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
  5. ^ a b "Reagila 1.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 9 August 2018. Archived from the original on 21 October 2020. Retrieved 20 October 2020.
  6. ^ a b c d e f "Vraylar- cariprazine capsule, gelatin coated Vraylar- cariprazine kit". DailyMed. 18 May 2019. Archived from the original on 24 October 2020. Retrieved 20 October 2020.
  7. ^ a b "Reagila EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 October 2020. Retrieved 20 October 2020.
  8. ^ Laszlovszky I, Barabássy Á, Németh G (July 2021). "Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety". Advances in Therapy. 38 (7): 3652–3673. doi:10.1007/s12325-021-01797-5. PMC 8279990. PMID 34091867.
  9. ^ Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, et al. (May 2012). "Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors". Bioorganic & Medicinal Chemistry Letters. 22 (10): 3437–3440. doi:10.1016/j.bmcl.2012.03.104. PMID 22537450.
  10. ^ Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmári B, Németh G, et al. (June 2019). "Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study". The American Journal of Psychiatry. 176 (6): 439–448. doi:10.1176/appi.ajp.2018.18070824. PMID 30845817.
  11. ^ Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (April 2010). "Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile". The Journal of Pharmacology and Experimental Therapeutics. 333 (1): 328–340. doi:10.1124/jpet.109.160432. PMID 20093397. S2CID 42933132.
  12. ^ "FDA approves new drug to treat schizophrenia and bipolar disorder" (Press release). U.S. Food and Drug Administration. 17 September 2015. Archived from the original on 26 January 2018. Retrieved 16 December 2019.
  13. ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  14. ^ "Generic Vraylar Availability". Drugs.com. 9 March 2023. Archived from the original on 26 March 2023. Retrieved 26 March 2023.
  15. ^ a b c Citrome L (February 2013). "Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability". Expert Opinion on Drug Metabolism & Toxicology. 9 (2): 193–206. doi:10.1517/17425255.2013.759211. PMID 23320989. S2CID 36750662.
  16. ^ Do A, Keramatian K, Schaffer A, Yatham L (2021). "Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials". Frontiers in Psychiatry. 12: 769897. doi:10.3389/fpsyt.2021.769897. PMC 8712443. PMID 34970166.
  17. ^ Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN (March 2021). "Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies". International Clinical Psychopharmacology. 36 (2): 76–83. doi:10.1097/YIC.0000000000000344. PMC 7846289. PMID 33230026.
  18. ^ Tohen M (2021). "Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data". Drug Design, Development and Therapy. 15: 2005–2012. doi:10.2147/DDDT.S240860. PMC 8126799. PMID 34012253.
  19. ^ "Cariprazine hydrochloride for schizophrenia". Australian Prescriber. 44 (5): 170–171. October 2021. doi:10.18773/austprescr.2021.047. PMC 8542486. PMID 34728883.
  20. ^ a b c Citrome L (February 2013). "Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy". Advances in Therapy. 30 (2): 114–126. doi:10.1007/s12325-013-0006-7. PMID 23361833.
  21. ^ Veselinović T, Paulzen M, Gründer G (November 2013). "Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression". Expert Review of Neurotherapeutics. 13 (11): 1141–1159. doi:10.1586/14737175.2013.853448. PMID 24175719. S2CID 23557344.
  22. ^ a b Newman-Tancredi A, Kleven MS (August 2011). "Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties". Psychopharmacology. 216 (4): 451–473. doi:10.1007/s00213-011-2247-y. PMID 21394633. S2CID 5835943.
  23. ^ Stahl SM, ed. (2020). "Cariprazine". Prescriber's Guide: Stahl's Essential Psychopharmacology (7th ed.). Cambridge: Cambridge University Press. pp. 137–146. doi:10.1017/9781108921275.024. ISBN 978-1-108-92601-0. Archived from the original on 18 May 2024. Retrieved 11 October 2022.
  24. ^ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 22 May 2021. Retrieved 14 August 2017.
  25. ^ Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P (December 2018). "Involvement of 5-HT1A and 5-HT2A Receptors but Not α 2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo". Molecular Pharmacology. 94 (6): 1363–1370. doi:10.1124/mol.118.113290. PMID 30322874. S2CID 53096758.
  26. ^ Mohr P, Masopust J, Kopeček M (25 January 2022). "Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?". Frontiers in Psychiatry. 12: 781946. doi:10.3389/fpsyt.2021.781946. PMC 8821167. PMID 35145438.
  27. ^ Seeman P, Kapur S (July 2000). "Schizophrenia: more dopamine, more D2 receptors". Proceedings of the National Academy of Sciences of the United States of America. 97 (14): 7673–7675. Bibcode:2000PNAS...97.7673S. doi:10.1073/pnas.97.14.7673. PMC 33999. PMID 10884398.
  28. ^ a b c Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, et al. (November 2011). "Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents". Neurochemistry International. 59 (6): 925–935. doi:10.1016/j.neuint.2011.07.002. PMID 21767587. S2CID 140205658.
  29. ^ a b Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, et al. (December 2011). "Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography". Psychopharmacology. 218 (3): 579–587. doi:10.1007/s00213-011-2343-z. PMC 3210913. PMID 21625907.
  30. ^ Jethwa KD (September 2015). "Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm". BJPsych Advances. 21 (5): 342–344. doi:10.1192/apt.bp.114.013797. S2CID 146670706.
  31. ^ Citrome L, Yatham LN, Patel MD, Barabássy Á, Hankinson A, Earley WR (June 2021). "Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression". Journal of Affective Disorders. 288: 191–198. doi:10.1016/j.jad.2021.03.076. PMID 33915374. S2CID 233462432.
  32. ^ Cohen LJ (1994). "Risperidone". Pharmacotherapy. 14 (3): 253–65. doi:10.1002/j.1875-9114.1994.tb02819.x. PMID 7524043.
  33. ^ "Full agonists, partial agonists and inverse agonists | Deranged Physiology". Archived from the original on 14 February 2023. Retrieved 21 February 2023.
  34. ^ Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology. 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. S2CID 26101524.
  35. ^ a b Gründer G (July 2010). "Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression". Current Opinion in Investigational Drugs. 11 (7): 823–832. PMID 20571978.
  36. ^ Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, et al. (March 2016). "An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression". The American Journal of Psychiatry. 173 (3): 271–281. doi:10.1176/appi.ajp.2015.15020164. PMID 26541814.
  37. ^ "Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder". ClinicalTrials.gov. U.S. National Library of Medicine. Archived from the original on 6 December 2018. Retrieved 6 December 2018.
  38. ^ "AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (major depressive disorder) for the Adjunctive Treatment of Major Depressive Disorder". AbbVie (Press release). Archived from the original on 16 October 2022. Retrieved 11 October 2022.
  39. ^ "U.S. FDA Approves Vraylar (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder" (Press release). AbbVie. 16 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023 – via PR Newswire.

Read other articles:

Kompleks piramida Senusret III, piramida Itakayt adalah yang ketiga dari kanan atas Itakayt merupakan seorang putri Mesir Kuno dari Dinasti ke-12, pada sekitar tahun 1800 SM. Ia terutama dikenal dari piramida kecilnya di samping Senusret III di Dahshur.[1] Ia bergelar putri raja dari tubuhnya, berkuasa, anggun dan dicintai. Piramida Piramidanya di sisi utara piramida raja berukuran sekitar 16.80 meter di dasar, dan dulunya juga tingginya 16.80 meter tingginya. Dibangun dari batu bata lum…

本條目存在以下問題,請協助改善本條目或在討論頁針對議題發表看法。 此條目需要补充更多来源。 (2018年3月17日)请协助補充多方面可靠来源以改善这篇条目,无法查证的内容可能會因為异议提出而被移除。致使用者:请搜索一下条目的标题(来源搜索:羅生門 (電影) — 网页、新闻、书籍、学术、图像),以检查网络上是否存在该主题的更多可靠来源(判定指引)。 此…

جائزة بلجيكا الكبرى 1981 السباق 5 من أصل 15 في بطولة العالم لسباقات الفورمولا واحد موسم 1981 السلسلة بطولة العالم لسباقات فورمولا 1 موسم 1981  البلد بلجيكا  التاريخ 17 مايو 1981 مكان التنظيم بلجيكا طول المسار 4.011 كيلومتر (2.492 ميل) المسافة 216.594 كيلومتر، (134.585 ميل) حالة الطقس جاف أول …

الكتيبة الخاصة 71 شعار الكتيبة الخاصة 71 الدولة  الأردن التأسيس 1973 - حتى الان الاسم الأصلي الكتيبة الخاصة 71 (الأردن) اسم آخر الوحدة الخاصة 2 القيادة رتبة القائد مقدم تعديل مصدري - تعديل   القوات الأردنية الخاصة 71 هي فرقة مكافحة الإرهاب والعمليات الخاصة الأردنية والتي تحمي ا…

American politician For other people named Samuel Sawyer, see Samuel Sawyer (disambiguation). Samuel Locke SawyerMember of the U.S. House of Representativesfrom Missouri's 8th districtIn officeMarch 4, 1879 – March 3, 1881Preceded byBenjamin Joseph FranklinSucceeded byRobert T. Van Horn Personal detailsBorn(1813-11-27)November 27, 1813Mont Vernon, New Hampshire, USDiedMarch 29, 1890(1890-03-29) (aged 76)Independence, Missouri, USPolitical partyDemocraticProfessionlawy…

American politician Richard Howard Ichord Jr.Member of the U.S. House of Representativesfrom Missouri's 8th districtIn officeJanuary 3, 1961 – January 3, 1981Preceded byA. S. J. CarnahanSucceeded byR. Wendell BaileyMember of the Missouri House of RepresentativesIn office1952–1960 Personal detailsBorn(1926-06-27)June 27, 1926Licking, MissouriDiedDecember 25, 1992(1992-12-25) (aged 66)Houston, MissouriPolitical partyDemocraticAlma materUniversity of Missouri Richard H…

This article needs to be updated. Please help update this article to reflect recent events or newly available information. (May 2022) Cabbage growing in a Veggie unit[1] The Vegetable Production System (Veggie) is a plant growth system developed and used by NASA in outer space environments. The purpose of Veggie is to provide a self-sufficient and sustainable food source for astronauts as well as a means of recreation and relaxation through therapeutic gardening.[2] Veggie was de…

2022 song by IShowSpeed World CupSingle by IShowSpeedReleasedNovember 4, 2022 (2022-11-04)RecordedSeptember 21, 2022[1]StudioMetropolis (London)[1]GenreHip hop[2]Length4:16LabelWarnerSongwriter(s) Darren Watkins Jr. Ryan Wage Producer(s) IShowSpeed WageeBeats Joe Grasso IShowSpeed singles chronology Ronaldo (Sewey) (2022) World Cup (2022) Dogs (2023) Music videoWorld Cup on YouTubeAudio sampleIShowSpeed - World Cupfilehelp World Cup is a song by American Yo…

Perekacitraan 3D adalah proses grafik komputer 3D yang mengubah model 3D menjadi gambar 2D di komputer . Rekacitra 3D mungkin menyertakan efek fotorealistik atau gaya non-fotorealistik . Cara merekacitra Rekacitra 3D fotorealistik dari 6 kipas komputer menggunakan rendering radiositas, DOF, dan materi prosedural Perekacitraan adalah proses akhir pembuatan gambar atau animasi 2D sebenarnya dari adegan yang telah disiapkan. Hal ini dapat dibandingkan dengan mengambil foto atau merekam adegan setel…

Chemical compound ABT-418Identifiers IUPAC name 3-Methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole CAS Number147402-53-7 NPubChem CID119380ChemSpider106627 YUNIIB9I6MZL7BWChEMBLChEMBL274525 YCompTox Dashboard (EPA)DTXSID10163711 Chemical and physical dataFormulaC9H14N2OMolar mass166.224 g·mol−13D model (JSmol)Interactive image SMILES CC1=NOC(=C1)[C@@H]2CCCN2C InChI InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1 YKey:ILLGYRJAYAAAEW-QMM…

Markas Banca Monte dei Paschi di Siena di Siena Bankir pedagang Cornelius Berenberg, anggota keluarga Berenberg. Kakeknya mendirikan Berenberg Bank tahun 1590 Daftar bank tertua ini mencakup lembaga-lembaga keuangan yang masih beroperasi dengan identitas hukum yang sama sejak didirikan sampai sekarang. Meski saat ini masih ada tujuh bank yang didirikan pada abad ke-17 dan 16 bank yang didirikan pada abad ke-18, daftar ini dipuncaki oleh dua bank yang masing-masing didirikan pada abad ke-15 dan 1…

Multi use stadium in Granada, Spain (opened 1995) Los CármenesUEFA Full nameNuevo Estadio de Los CármenesLocationCalle Pintor Manuel Maldonado, s/n. 18008 - Granada, SpainCoordinates37°9′11″N 3°35′45″W / 37.15306°N 3.59583°W / 37.15306; -3.59583OwnerAyuntamiento de GranadaCapacity19,336 [1]Field size105 × 68 mSurfaceGrassConstructionBuilt1993–1995Opened16 May 1995Renovated2011TenantsGranada CF (1995–present)CP Granada 74 (2002–2004)Granada Atl…

Questa voce sull'argomento politici burundesi è solo un abbozzo. Contribuisci a migliorarla secondo le convenzioni di Wikipedia. Melchior Ndadaye Presidente del BurundiDurata mandato10 luglio 1993 –21 ottobre 1993 PredecessorePierre Buyoya SuccessoreFrançois Ngeze Dati generaliPartito politicoFronte per la Democrazia in Burundi Melchior Ndadaye (Nyabihanga, 28 marzo 1953 – Bujumbura, 21 ottobre 1993) è stato un politico burundese. Quarto Presidente della repubblica…

This article is about the restaurant in New York City. For other uses, see Odeon. Restaurant in New York, United StatesThe OdeonThe restaurant's exterior in 2009Restaurant informationStreet address145 West BroadwayCityNew York CityStateNew YorkCountryUnited StatesCoordinates40°43′01″N 74°00′28″W / 40.716967°N 74.007841°W / 40.716967; -74.007841 The Odeon is a restaurant in New York City.[1] The restaurant opened in 1980, in space previously occupied by…

Disambiguazione – Divizia A rimanda qui. Se stai cercando altre competizioni rumene o moldave, vedi Divizia A (disambigua). SuperLiga RomânieiAltri nomiLiga I, Divizia A Sport Calcio TipoSquadre di club FederazioneFRF Paese Romania OrganizzatoreLPF TitoloCampione di Romania Cadenzaannuale Aperturaluglio Chiusuragiugno Partecipanti16 squadre Formulagirone all'italiana+poule scudetto o retrocessione Retrocessione inLiga II Sito Internetlpf.ro StoriaFondazione1909 Numero edizioni105…

2010 MTV Video Music Awards Tanggal September 12, 2010 Tempat Nokia Theatre Host Chelsea Handler[1] 2010 MTV Video Music Awards diadakan pada 12 September, 2010 di Nokia Theatre di Los Angeles, memberi penghargaan pada video musik terbaik tahun sebelumnya. Chelsea Handler menjadi host acara, perempuan pertama yang melakukan ini semenjak 1994 MTV Video Music Awards.[1] Keseluruhan, acara menangkan 11,4 juta penonton — penonton terbanyak sejak 2002[2] Nominasi Pemenang di…

CapucheCapuche d'un manteau d'hiver inuit.CaractéristiquesType Couvre-chefMatière lainecotonautre...modifier - modifier le code - modifier Wikidata La capuche[1] ou le capuchon[2] (parfois aussi nommé « capuce » chez les moines) est une coiffe conçue soit pour encadrer le visage, soit pour le cacher ; de fait, il a généralement une forme de voûte. La capuche fait souvent partie intégrante d'un vêtement, d'un manteau ou d'un imperméable (une sorte de grand bonnet qui co…

State Correctional Institution – RockviewLocationBenner Township, Centre County, Pennsylvania, USAOpened1915Managed byPennsylvania Department of Corrections SCI Rockview -- SCI Benner Township can be seen in the background SCI Rockview overhead view The State Correctional Institution – Rockview (SCI Rockview) is a Pennsylvania Department of Corrections prison located in Benner Township, Pennsylvania, 5 miles (8.0 km) away from Bellefonte.[1][2] A portion of the prison gr…

Greek civilization from c. 1200 BC to c. 600 AD The Parthenon, a temple dedicated to Athena, located on the Acropolis in Athens, is one of the most representative symbols of the culture and sophistication of the ancient Greeks. Part of a series on the History of Greece Neolithic Greece Pelasgians Greek Bronze Age Helladic Cycladic Minoan Mycenaean Greece 1750 BC–1050 BC Ancient Greece Greek Dark Ages 1050 BC–750 BC Archaic Greece 800 BC–480 BC Classical Greece 500 BC–323BC Hellenistic Gr…

South Slavic circle dance This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Kolo dance – news · newspapers · books · scholar · JSTOR (April 2014) (Learn how and when to remove this template message) Serbian kolo from Šumadija Serbian kolo from Timok Serbian kolo from Vranje Kolo (Serbian Cyrillic: Коло)…

Kembali kehalaman sebelumnya